Dean F. Wong, MD, PhD, professor of radiology for Mallinckrodt Institute of Radiology (MIR) at Washington University School of Medicine in St. Louis, led a positron emission tomography (PET) clinical study that shows promise for a new treatment option for schizophrenia.
The collaborative study with LB Pharmaceuticals Inc. was designed to evaluate dopamine receptor occupancy (how effectively a drug occupies its target receptor) of LB-102. LB-102 is a patented variant of amisulpride, a drug used to treat schizophrenia in Europe for decades.
The study indicates that LB-102 demonstrated unexpectedly prolonged dopamine receptor engagement, potentially offering schizophrenia patients the benefits of amisulpride at a lower dose. Wong and representatives from LB Pharmaceuticals shared their findings at the American College of Neuropsychopharmacology’s 60th Annual Meeting in San Juan, Puerto Rico.
The next step is a double-blind, placebo-controlled Phase 2 clinical study expected to begin the first half of 2022. Read more about the study here.